Navigation Links
Beaumont Health System launches research trial of bioresorbable heart scaffold
Date:7/29/2013

Beaumont Health System has joined a multicenter, international research study of a new temporary heart device that helps keep an artery open following angioplasty, then is broken down and absorbed by the body.

The research will compare the effectiveness of the new "disappearing" device, the AbsorbTM Bioresorbable Vascular Scaffold made by health care company Abbott, with drug-eluting, metal stents that are commonly placed in heart arteries as a permanent implant. Absorb is referred to as a scaffold to indicate it is temporary in nature, unlike a permanent metallic stent. It is made of polylactide, a material commonly used in medical implants such as dissolving sutures. Coronary artery stents were approved for use in the United States in 1994. Similar to a mesh tube, stents prop open a heart artery after a blockage is cleared with a procedure called angioplasty.

In angioplasty, a doctor threads a catheter, or hollow tube, into the arteries of the heart through a small incision in the groin or wrist, with a tiny balloon at its tip that, once inflated, pushes a blockage against the artery wall to open the artery and improve blood flow to the heart. Angioplasty is often followed by insertion of a stent coated with medication, called a drug-eluting stent, at the site of the blockage to keep the vessel open and prevent renarrowing. Metallic stents are a permanent implant in the wall of the artery.

"Stents have revolutionized the treatment of heart blockages by helping many patients to avoid having repeat angioplasty procedures and in some cases open-heart surgery," says Amr Abbas, M.D., Beaumont's director of interventional cardiology research and the study's principal investigator. "This new bioabsorbable vascular scaffold is the latest technique in heart treatment in interventional cardiology."

Research has shown that the support of a coronary stent is only needed for a few months after implantation while the artery wall is healing. Although researchers hoped to create a temporary scaffold that dissolved after doing its job, there were many scientific challenges. A decade ago, scientists at Abbott started development of Absorb and now Abbott is the first company in the world to begin testing a bioresorbable vascular scaffold in patients in the United States.

The Absorb BVS is available in Europe, Middle East and parts of Asia. It is an investigational device not available for sale in the U.S.

ABSORB III will enroll approximately 2,250 patients, the majority in the U.S.


'/>"/>

Contact: Angela Blazevski
angela.blazevski@beaumont.edu
248-551-0445
Beaumont Health System
Source:Eurekalert

Related medicine news :

1. Beaumont Study: Nerve Stimulation Helps with Overactive Bladder
2. Beaumont Health System Recognized as an American Heart Association Fit-Friendly Worksite
3. Beaumont Cardiologist Kavitha Chinnaiyan, M.D., Receives Excellence in Research Award
4. Beaumont cardiologist Kavitha Chinnaiyan, M.D., receives excellence in research award
5. Beaumont receives national green award
6. Beaumont recipient of 2013 Dove Award from the Arc of Oakland County
7. Beaumont Childrens Hospital pediatrician inducted into Legends of Neonatology Hall of Fame
8. Beaumont doctors call for training to reduce sudden cardiac arrest fatalities in schools
9. Gulfside Dental Visits First Steps Daycare in Beaumont, TX
10. Gulfside Dental Celebrating Seniors Mardi Gras at Beaumont Civic Center
11. Gulfside Dental Now Offers LUMINEERS in Beaumont, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... Southlake, Texas (PRWEB) , ... April 29, 2016 , ... ... and neck pain, is proud to announce one of their physicians has been invited ... Osteopathic Family Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. ...
(Date:4/29/2016)... ... ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of skin ... More than 10,000 people are expected to die of melanoma this year. The risk increases ... of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, ... round of funding led by Eastside Partners, with participation from existing investor Martin ... customer base and accelerate its technology and product roadmap. , “Jvion ...
(Date:4/29/2016)... ... ... Nike Softball Camp at the College of Brockport in New York is ... 10-18. All facets of the game will be covered; hitting, fielding, base-running, and team ... the finest softball facilities in the region. The outstanding professional college staff complement and ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , le 27 Avril 2016 ... a progressé de +5% sur le trimestre, soutenu ... de consommables  Croissance de +16% des ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; ... confocale laser, annonce aujourd,hui son chiffre d,affaires pour ...
(Date:4/27/2016)... April 27, 2016 Elekta today ... platform will be the focal point of seven scientific ... European Society for Radiotherapy & Oncology, taking place April ... a state-of-the-art radiotherapy system and a high-field MRI scanner ... see the patient,s anatomy in real time. The MR-linac ...
(Date:4/27/2016)... , April 27, 2016   Zillion ... digital health technology platform, which specializes in live ... into scalable digital products, Zillion enables companies to ... empower consumers to take control of their health. ... video conferencing – including one-to-one, group and webcast ...
Breaking Medicine Technology: